One of the biggest challenges in cancer medicine today is selecting the right treatment for the right patient. Sequencing tumours alone does not solve the problem of finding the right treatments for cancer patients. Most patients have more than one medication either in combination therapy for cancer or for treating a comorbid condition. BioXplor's network pharmacology system uniquely prioritizes the right drug combinations based on safety and efficacy insights, while avoiding drug-drug interactions which can lead to serious adverse events.
BioXplor's network pharmacology analysis uniquely prioritizes treatments for complex diseases like cancer based on safety and efficacy insights from multiple unstructured and disparate data sources. Synergistic Drug Combinations can be more effective and less toxic with reduced drug resistance than monotherapies. Antagonistic Drug Interactions can cause severe adverse drug reactions in patients. BioXplor's system uses an evidence-baed approach to prioritize these treatments and detect potential issues with drug combinations and interactions.
Network Pharmacology Analysis
Access Case Studies
1 Drug Combinations for COVID-19
Prioritization of synergistic anti-inflammation and anti-viral drug combinations based on safety and efficacy profiles, including combinations by stage of development from pre-clinical to post0approval.
2 Drug Combinations for Lipedema
Pathway analysis to identify novel drug targets for a Lipedema, a rare fat disorder, and the prioritization of safe and effective treatments with evidence supporting Lipedema treatment.